Metronomic capecitabine for stage III stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a low-dose, frequent regimen of the chemotherapy drug capecitabine (taken as a pill) to see if it can help prevent stage III stomach cancer from coming back after surgery. It's for people who have had their stomach cancer completely removed with a specific type of lymph node dissection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 80 years old.
- Diagnosed with stage III stomach cancer that is adenocarcinoma (a common type).
- Had surgery to completely remove the cancer with a D2 lymph node dissection.
- Good physical condition (able to do daily activities without problems) and expected to live more than 6 months.
- No prior chemotherapy, radiotherapy, immunotherapy, or targeted therapy for this cancer.
- No other active cancers or serious health conditions like uncontrolled heart, lung, kidney, or liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares taking capecitabine pills after curative surgery versus no further treatment. It aims to lower the chance of stomach cancer coming back in people with stage IB disease that has extra risk factors.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.